Navigation Links
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
Date:10/20/2015

SAN DIEGO, Oct. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has expanded the clinical efforts for NBI-98854 (Valbenazine), a highly selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, by initiating a Phase II clinical trial in adults with Tourette syndrome.  

The T-Forward study is a randomized, double-blind, placebo-controlled, multi-dose, parallel group, study of up to 90 adults. Subjects will receive once-daily dosing of NBI-98854 during an eight-week treatment period to assess the safety, tolerability and efficacy of NBI-98854 in Tourette patients. The primary endpoint of this study is a change from baseline of placebo vs. active scores utilizing the Yale Global Tic Severity Scale at the end of Week 8. Data readout from this study is expected later in 2016.

"Evaluation of Valbenazine in adults with Tourette syndrome is another important step in fully exploring its potential in movement disorders," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences. "We look forward to our T-Force study readout of children and adolescents with Tourette's during this quarter, and our anticipated NDA filing of NBI-98854 for tardive dyskinesia in 2016."

T-Forward Study Design

The T-Forward study is a randomized, double-blind, placebo-controlled, multi-dose, parallel group, Phase II study to evaluate the safety, tolerability and efficacy of NBI-98854 in adults with moderate to severe Tourette syndrome. Two once-daily fixed doses of NBI-98854 will be evaluated vs. placebo in a 1:1:1 randomization. The three-arm study will evaluate up to 90 patients over eight weeks of dosing followed by two weeks off-drug at approximately 40 study centers in the United States. The primary endpoint of this study is a change from baseline of placebo vs. active scores utilizing the Yale Global Tic Severity Scale at the end of Week 8. Tourette symptoms will also be evaluated via the Premonitory Urge for Tics Scale as well as Clinical Global Impression of Change scales, among others.

About Tourette Syndrome

Tourette syndrome is a neurological disorder that consists of rapid, non-rhythmic stereotyped motor and vocal tics. Motor tics are typically characterized by facial grimacing, head jerks, extremity movements and other dystonic movements. Vocal tics typically include grunting, throat clearing, and repeating words and phrases. The average age at onset for Tourette syndrome is at six years, with symptoms reaching their peak severity at approximately age ten. Tourette syndrome is more commonly diagnosed in males than females and may be associated with attention deficit hyperactivity disorder and obsessive compulsive disorder. There are approximately 400,000 people with Tourette syndrome in the United States.

About NBI-98854

VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) in pre-synaptic neurons. NBI-98854, developed in the Neurocrine laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines, thereby reducing the likelihood of "off-target" side effects. NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive monoamine depletion.

Modulation of neuronal dopamine levels in diseases such as tardive dyskinesia, Tourette syndrome, Huntington's chorea, schizophrenia, and tardive dystonia, which are characterized, in part, by a hyperdopaminergic state, should provide symptomatic benefits for patients with these diseases.

The Company has two distinct Investigational New Drug Applications related to NBI-98854, tardive dyskinesia and Tourette syndrome, open with the Division of Psychiatry Products at the FDA. Neurocrine has received Breakthrough Therapy Designation from the FDA for NBI-98854 in the treatment of tardive dyskinesia and expects to file a New Drug Application for tardive dyskinesia in 2016.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with NBI-98854 development. Specifically, the risks and uncertainties the Company faces include risks that NBI-98854 development activities may not be completed on time or at all; risks that NBI-98854 development activities may be delayed for regulatory or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that NBI-98854 is safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that NBI-98854 regulatory submissions may not occur or be submitted in a timely manner; risks that  NBI-98854 may not obtain regulatory approval or that the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may make adverse decisions regarding NBI-98854; risks that NBI-98854 may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with the Company's dependence on third parties for development and manufacturing activities related to NBI-98854; risks that the Company will be unable to raise additional funding, if required, to complete development of NBI-98854; risks and uncertainties relating to competitive products and technological changes that may limit demand for NBI-98854; and other risks described in the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2015. Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
2. Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors
3. Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference
4. Neurocrine Biosciences to Present at the Baird 2015 Healthcare Conference
5. Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study
6. Neurocrine Biosciences Reports Second Quarter 2015 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2015 Results
8. Neurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia
9. Neurocrine Biosciences to Host Analyst and Investor Day in New York City on May 21, 2015
10. Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
11. Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2019)... ... December 06, 2019 , ... ... implementation this month, Kenall is introducing the CSEDOIC luminaire series. CSEDOIC fixtures are ... now requires the unpacking of hazardous drugs (HDs) and HD-active pharmaceutical ingredients from ...
(Date:12/6/2019)... ... December 06, 2019 , ... ... announce an expansion in services. While Kindred Nutrition and Wellness will continue ... they are now happy to offer Individual and Family Therapy and Yoga. , ...
(Date:12/6/2019)... ... December 06, 2019 , ... The Multiple System Atrophy Coalition ... bold new initiative to kickstart MSA research collaborations. Multiple system atrophy is ... by $3 million in new bequests earmarked for research and combined with ongoing ...
Breaking Medicine Technology:
(Date:12/8/2019)... ... , ... Intelligent.com, a trusted resource for online degree rankings ... 2020. The comprehensive research guide is based on an assessment of 104 accredited ... quality, graduation rate, reputation, and post-graduate employment. , The 2020 rankings are ...
(Date:12/6/2019)... Conn. (PRWEB) , ... December 06, 2019 , ... ... is consistently recognized for its innovations and excellence in patient care. On December ... that standard of excellence at the Health Care Heroes Awards at the Hartford ...
(Date:12/6/2019)... ... 06, 2019 , ... COMPLIANCY GROUP is proud to announce ... Society. Compliancy Group is dedicated to educating and assisting Wyoming Medical Society’s members ... the standards set forth by the Health Insurance Portability and Accountability Act (HIPAA). ...
(Date:12/5/2019)... ... December 05, 2019 , ... A cohort of plastic ... to help their patients more easily detect ruptured silicone gel implants. Dr. Herluf ... and reporting on his experience. While the FDA currently recommends regular MRI scans ...
(Date:12/5/2019)... ... 05, 2019 , ... It’s been an impactful year for ... people embrace, achieve, and maintain a healthy lifestyle to giving generously to communities ... mission of impacting world health, so it’s gratifying to look back on the ...
Breaking Medicine News(10 mins):